Ovarian cancer is a deadly gynecologic malignancy for which novel biomarkers and therapeutic targets are imperative for improving survival. Previous studies have suggested the expression pattern of linker histone variants as potential biomarkers for ovarian cancer. To investigate the role of histone H1 in ovarian cancer cells, we characterize individual H1 variants and overexpress one of the major somatic H1 variants, H1.3, in the OVCAR-3 epithelial ovarian cancer cell line. We find that overexpression of H1.3 decreases the growth rate and colony formation of OVCAR-3 cells. We identify histone H1.3 as a specific repressor for the noncoding oncogene H19. Overexpression of H1.3 suppresses H19 expression, and knockdown of H1.3 increases its expression in multiple ovarian epithelial cancer cell lines. Furthermore, we demonstrate that histone H1.3 overexpression leads to increased occupancy of H1.3 at the H19 regulator region encompassing the imprinting control region (ICR), concomitant with increased DNA methylation and reduced occupancy of the insulator protein CTCF at the ICR. Finally, we demonstrate that H1.3 overexpression and H19 knockdown synergistically decrease the growth rate of ovarian cancer cells. Our findings suggest that H1.3 dramatically inhibits H19 expression, which contributes to the suppression of epithelial ovarian carcinogenesis. Cancer Res; 74(22); 6463-73. Ó2014 AACR.
Introduction
Ovarian cancer has the highest mortality rate among gynecologic malignancies and is currently the fourth most common cancer in women. Each year, more than 22,000 women are diagnosed with ovarian cancer in the United States and about 15,000 women die of the disease, primarily due to difficulties in early diagnosis and poor prognosis (1, 2) . The etiology of ovarian cancers involves both genetic and epigenetic alterations, although the underlying mechanisms are not well-understood (refs. 3-5 and references therein). Recently, the expression of linker histone variants has been suggested as potential biomarkers for ovarian cancers (6) . However, the role of linker histone variants in ovarian cancer cells has not been explored.
H1 linker histones interact with the nucleosomes at the entry and exit sites of the nucleosomal DNA and facilitate the folding of chromatin into higher order structures (7) . In mammals, there are eleven H1 variants identified, including seven somatic H1 variants (H1.0 to H1.5 and H1.x) and four tissue-specific H1s (testis-specific H1t, H1T2, HILS1, and oocyte-specific H1oo; ref. 8). H1.1 to H1.5 are five major somatic H1 variants in both dividing and nondividing cells, whereas H1.0 mainly accumulates in differentiated cells. H1x is present in very low amount and found to have a higher expression in neuroendocrine cells (8) . The heterogeneity and expression pattern of H1s are conserved from mouse to human, suggesting that the individual variants may have unique properties and functions.
Besides mediating higher order chromatin folding, linker histone H1 has been shown to regulate gene expression in vivo in a specific manner (9) . However, it is not clear whether those genes are directly regulated by a specific H1 variant. Here, we report the identification of an important noncoding H19 gene as a direct target specifically regulated by H1.3 in ovarian cancer cells.
Aberrant expression of H19 occurs in ovarian cancer and other types of cancers (10) (11) (12) . H19 is often overexpressed in ovarian cancer and has been suggested as a biomarker for ovarian cancer (13) . Ample studies show that H19 is essential for tumor growth and H19 overexpression contributes to tumorigenesis (reviewed in ref. 14) , although its role in ovarian cancer has not been well studied. H19 is an oncofetal gene located on human chromosome 11 and is highly expressed in fetal tissues but suppressed in most tissues after birth (15, 16) .
H19 belongs to an imprinted gene family controlled by the imprinting control region (ICR), which is important for mammalian development (17, 18) . Expressed from the maternal allele, H19 encodes for a spliced, capped, and polyadenylated noncoding RNA highly conserved in evolution (19) . It is also a precursor for a microRNA, miR-675, which targets genes essential for growth, development, and carcinogenesis, such as RB and Igf1r (20) (21) (22) . The H19 locus was recently found to produce antisense transcripts, including H19 opposite tumor suppressor (HOTS) and a long intergenic transcript, 91H, indicating the complexity of this region (23, 24) . Moreover, H19 expression has been shown to be regulated by chromatin structure and epigenetic mechanisms, including DNA methylation, CTCF insulator, and enhancer activities (reviewed in refs. 25, 26) .
In this study, we use overexpression and shRNA knockdown approaches to modulate the expression levels of H1s and H19 mRNA in OVCAR-3 cells. We find that linker histone H1.3 directly represses the expression of the H19 gene in ovarian epithelial cancer cells by preferential occupancy at the ICR of H19 and regulating DNA methylation at this region. We also show that H1.3 overexpression suppresses the growth and clonogenicity in ovarian cancer cells and has synergistic effects with H19 knockdown on growth inhibition of epithelial ovarian cancer cells. These results suggest H1.3 as a potent epigenetic regulator for H19 and a novel mechanism by which H1.3 suppresses tumorigenesis in epithelial ovarian cancer cells.
Materials and Methods

Cell culture
OVCAR-3 cells were cultured in RPMI-1640 (Fisher) media supplemented with 20% fetal bovine serum (FBS; Gemini), 100 U/mL penicillin, and 100 mg/mL streptomycin (Life Technologies). OV-90 cells were cultured in a 1:1 mixture of MCDB 105 medium (Sigma) and medium 199 (Sigma) supplemented with 15% FBS, 1.85 g/L sodium bicarbonate, 100 U/mL penicillin, and 100 mg/mL streptomycin. SK-OV-3 cells were cultured in McCoy 5a modified medium (Sigma) supplemented with 10% FBS, 2.2 g/L sodium bicarbonate, 100 U/mL penicillin, and 100 mg/mL streptomycin. All cells were cultured in a humidified incubator with 5% CO 2 at 37 C.
Vectors construction, cell transfection, and stable cell lines generation The coding sequences of human H1 variant genes were cloned into a modified pcDNA3 vector with FLAG sequence (5 0 -GACTACAAAGACGATGACGACAAG-3 0 ) at the N-terminal to the start codon and sequence verified. The vector containing H19 gene was purchased from Genescript, and the H19 gene was inserted into pcDNA3 vector and sequence verified.
OVCAR-3 cells were transfected with pcDNA-H1s or pcDNA-H19 vectors by Lipofectamine 2000 (Life Technologies) according to the manufacturer's manual. Two days posttransfection, the cells were treated with 400 mg/mL G418 (Geneticin, Life Technologies) for 4 to 5 weeks and resistant clones were isolated and screened. OV-90 cells were transfected with H1.1 or H1.3 expression vectors by Nucleofector Kits (Lonza) following the manufacturer's protocol, and cells were harvested 2 days posttransfection and analyzed.
pTRIPz (inducible), pGIPz (stable) shRNA vectors, and TransLenti Viral Packaging Systems were purchased from Thermo Scientific. Viral particles containing vectors expressing shRNA for H19 or H1.3 were produced according to the manufacturer's manual and used to transduce OVCAR-3, OV-3/H1.3(H), and SK-OV-3 cells. The cells were subsequently sorted (BD FACS Aria III Cell Sorter, Beckman Coulter) by red fluorescence protein or green fluorescence protein expression to enrich the shRNA-expressing cells.
RNA isolation and real-time PCR
RNAs were extracted with TRIzol (Life Technologies) according to the manufacturer's instructions and further cleaned using RNeasy Mini Kit (Qiagen). Total RNA (2.5 mg) was reverse transcribed using Superscript III kit (Life Technologies) according to the manufacturer's protocol, and cDNAs were subsequently analyzed by quantitative real-time PCR (qRT-PCR). H19 primers were as follows: F: 5 0 -ACCACTGCAC-TACCTGACTC-3 0 and R: 5 0 -CCGCAGGGGGTGGCCATGAA-3 0 . GAPDH primers were published previously (6) . The relative expression of selected genes was quantified and analyzed by real-time PCR using iQ SYBR Green PCR Supermix kit (Bio-Rad Laboratories) as previously described (27) . All samples were typically analyzed in triplicates in at least three independent runs.
Western blotting
The cells were lysed in lysis buffer [30 mmol/L Tris, pH 8.0, 150 mmol/L NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 0.1% NP-40, proteinase inhibitor tablet (Roche)] and total histones were extracted as previously described (27) . Western blotting assays were performed according to the manufacturer's manual (Bio-Rad). The primary antibodies used are against: FLAGtag (Sigma, F1804), H1.2 (Abcam, ab4086), H1.3 (Abcam, ab24174), phospho-H1.4 (Sigma, H7664), H1.5 (Abcam, ab24175), H1.0 (Santa Cruz, sc-56695), and b-actin (Sigma, A5441). The secondary antibodies are IRDye680 goat antirabbit (Li-COR, 926-32221), IRDye800 goat anti-rabbit (Rockland, 611-0132-122), or goat anti-mouse (Molecular Probes, A21058). Signals were visualized using Odyssey Infrared Imaging System (LI-COR Biosciences).
Growth curves, MTT and clonogenic assays
For growth curves and MTT cell proliferation assays, 3 Â 10 4 cells per well of a 12-well plate and 1,500 cells per well of a 96-well plate were seeded in triplicates, respectively. Cell numbers were counted with Multisizer Coulter Counter (Beckman Coulter), and MTT assay was performed every 2 days for indicated days. Values are expressed as mean AE SD and statistical analyses were performed using GraphPad Prism statistical software. For MTT assay, 2 hours after incubation with MTT compound (Sigma), mitochondrial succinate dehydrogenase in metabolically active cells formed insoluble formazan crystals, which were resolubilized with stop solution (10% SDS, 0.1% HCl). The amount of formazan crystals produced by the cells was proportional to metabolic activity, which was measured by spectrometer at 570 nm wavelength. For colony-forming assay, 100, 300, and 1,000 cells were seeded on 3.5-cm dishes in triplicates and were cultured in a humidified incubator with 5% CO 2 for 4 weeks as previously described with modifications (28) . Medium was changed every 3 days. After incubation, the cell colonies were fixed with PBS:methanol (1:1 ratio) for 2 minutes and then incubated in methanol for 10 minutes and air dried. The colonies were stained by adding 3 mL 1% crystal violet for 10 minutes and counted.
Microarray and data analysis Total RNAs were isolated with TRIzol reagent (Life Technologies), purified, labeled, and used for microarray hybridization to human Affymetrix ST1.0 array at Einstein Genomic Facility. Data were analyzed using RMA normalization in Expression Console (Affymetrix). Selected gene changes were confirmed using qRT-PCR. The results were normalized over the housekeeping gene GAPDH and compared with the controls. Cluster analysis was performed to group genes with altered expression more than 2-fold into subgroups according to their expression patterns (Cluster 3.0). Differentially expressed genes were analyzed with Ingenuity Pathway Analysis (IPA) Software (Qiagen) to determine the pathways or functional groups of genes involved. Gene ontology analysis was performed using DAVID (29) to obtain enriched biologic processes categories of statistical significance. Microarray data are available at the NCBI Gene Expression Omnibus (GEO) database under accession number GSE61692.
High-performance liquid chromatography
Histone proteins were extracted using 0.2 N sulfuric acid as previously described (27) . Hundred micrograms of total histone preparations was injected into a C18 reverse phase column (Vydac) on an AKTA UPC10 system (GE Healthcare). Fractions corresponding to the H1.2/H1.3/H1.4 peak from HPLC analysis were collected and subjected to mass spectrometric (MS) analysis on a Qstar XL MS/MS system (Applied Biosystems) with electrospray ionization (ESI) as the ionization method. Analyst QS software (Applied Biosystems) was used for data acquirement and analysis.
Chromatin immunoprecipitation, qChIP, and ChIP-seq
Chromatin immunoprecipitation (ChIP) assays were performed as previously described (30) with modifications. The following antibodies were used: anti-FLAG (Sigma, F1804), anti-CTCF (Santa Cruz, Sc15914), and anti-IgG (Millipore, 12-370). Purified ChIP-DNA was quantified using Qubit Fluorometer (Life Technologies). For qChIP, the amount of each specific DNA fragment in immunoprecipitates was determined by RT-PCR. PCR reactions were prepared with the iQ SYBR Green Supermix (Bio-Rad) and were analyzed in a MyIQ RealTime PCR Detection System (Bio-Rad). All samples were typically analyzed in triplicates in three independent experiments. For ChIP-seq, the libraries for massive parallel sequencing were prepared with the ChIP-seq Sample Preparation Kit (Illumina) according to the manufacturer's instructions. Sequencing was performed with Illumina HiSeq 2000 systems.
Sequence reads processing, alignment, and metagene analysis were performed as previously described (31) .
Bisulfite sequencing analysis
Genomic DNA was isolated from cells with QIAamp DNA kit (Qiagen). One microgram of DNA was treated with the CpGenome DNA Modification Kit (Millipore) according to the manufacturer's manual. Treated DNA was dissolved in 25 mL H 2 O, and 1 mL of treated DNA was used in each PCR reaction as previously described (9) . The following primers were used:
The PCR products were subsequently cloned using the TOPO TA cloning kit (Life Technologies), and clones containing the converted DNA inserts were selected for sequencing. DNA sequences were analyzed with BiQ analyzer.
Results
Analysis of individual H1 variants in OVCAR-3 cells
OVCAR-3 cell line is a well-characterized epithelial ovarian cancer cell line frequently used to study molecular mechanisms of ovarian cancer malignancies. This cell line was derived from a patient with epithelial ovarian adenocarcinomas, which represent about 90% of all ovarian cancer malignancies. We first characterized the expression of individual histone H1 variants by high-performance liquid chromatography (HPLC), MS, and Western blotting. Total histones were isolated from OVCAR-3 cells by sulfuric acid extraction and subjected to reverse-phase HPLC (RP-HPLC; Fig. 1A ). Three fractions of putative H1 variants were collected, lyophilized, and analyzed by MS and Western blotting. Fraction 3 was identified as a mixture of histones H1.2, H1.3, and H1.4 ( Fig. 1A and B) , three major somatic H1 variants abundantly expressed in adult tissues and cells. However, we noted that H1.3 protein level was much lower than H1.2 and H1.4 in OVCAR-3 cells, which is unusual given that histone H1.3 is ubiquitously expressed among different cell types and that H1.3 mRNA transcripts were present at high levels in OVCAR-3 cells (data not shown). To verify the identity of individual peaks of the HPLC fractions, we generated 6 stable cell lines with each overexpressing 1 of the 6 somatic histone H1 variants (H1.0-H1.5) in OVCAR-3 cells (designated as OV-3/H1 lines; Fig. 1C ). All six overexpressed somatic H1 variants were tagged by FLAG at the N-terminus, which was expected to maintain biochemical properties and functions of the respective H1 variants (31) . The total histones were extracted and analyzed by HPLC, and the eluted fractions were collected and verified by Western blotting (Fig. 1C ). These results demonstrate the peak identity and the relative amount of each linker histone variant in HPLC profile from OVCAR-3/ H1 cell lines.
Overexpression of histone H1.3 inhibits cell growth and colony formation Histone H1.3 is one of the major somatic H1 variants abundantly present in both dividing and nondividing cells.
The very low expression of endogenous H1.3 in OVCAR-3 cells provides a good experimental system for us to investigate the role of H1.3 in ovarian cancer cells using an overexpression approach. We generated multiple OV-3/H1.3 stable clones by overexpressing FLAG-H1.3 in OVCAR-3 cells and screened 48 clones by Western blotting using an anti-FLAG antibody ( Supplementary Fig. S1A ). HPLC/MS analysis of the histone extracts from the clone with the highest FLAG-H1.3 level [designated as OV-3/H1.3(H)] as well as Western blotting assays using anti-H1 variant antibodies demonstrated that FLAG-H1.3 co-eluted in the same fraction as the endogenous H1.3, suggesting similar biochemical properties of FLAG-H1.3 as the endogenous H1.3 (Fig. 1A, B, and D) . Western blotting and calculation of the individual H1 to nucleosome ratio from HPLC analysis indicated that the protein level of FLAG-H1.3 in OVCAR-3/H1.3(H) cells was significant, reaching about 16% of the total H1s in these cells ( Fig. 1D and E) .
To characterize the phenotypic changes caused by H1.3 overexpression, we compared the growth rate, metabolic activity, and colony-forming abilities of OVCAR-3 and OV-3/ H1.3(H). OV-3/H1.3(H) cells displayed reduced growth rate by growth curve and MTT assays ( Fig. 2A) . Knocking down H1.3 in OV-3/H1.3(H) cells by shRNA ( Supplementary Fig. S1B ) reverted this effect (Fig. 2A) . These results indicated that overexpression of H1.3 variant reduces cell proliferation and affects the metabolic activity in OVCAR-3. In addition, the clonogenic capacity of OV-3/H1.3(H) cells was severely impaired, forming 10 to 15 times fewer colonies than OVCAR-3 cells (Fig. 2B) . This inhibitory effect of H1.3 overexpression on colony formation was partially abolished by H1.3 knockdown using shRNA in OV-3/H1.3(H) cells (Fig. 2B) .
Overexpression of H1.3 leads to specific changes in gene expression
To identify genes and pathways affected by H1. Table S1 ). Results from RT-PCR of several differentially expressed genes showed expression changes comparable to that from microarrays (Supplementary Fig. S2) . Analysis of the molecular pathways and cellular processes altered in OV-3/H1.3(H) cells using IPA software indicated that cell proliferation, cell adhesion, programmed cell death, cell migration, and immune response were all affected. A representative IPA hit map of cell function and maintenance including H19 gene is shown in Fig. 2D . Gene ontology classification using DAVID (29) revealed that Table S2 ).
Oncogene H19 is a direct target of H1. 3 One of the most dramatically dysregulated genes in OVCAR-3 cells is H19, which was repressed 9-fold in OV-3/ H1.3(H) cells, ranked #2 in the most highly repressed genes (Supplementary Table S1 ). Expressing FLAG-H1.3 to low-medium level in OV-3/H1.3(L) cells (Supplementary Fig. S1A ) resulted in a medium reduction in H19 expression (Fig. 3A) , indicating a dosage-dependent effect of H1.3 on H19 expression. Knockdown histone H1.3 levels by stably expressing shRNA against H1.3 in OV-3/H1.3(H)/shH1.3 cells (Supplementary Fig.  S1B ) alleviated the repression of H19 by H1.3, whereas scrambled shRNA did not have such effects (Fig. 3A) . To further test whether the expression of H19 is directly dependent on the amount of histone H1.3, we generated OV-3/shH1.3(i) cell line in which the expression of endogenous H1.3 in OVCAR-3 cells was knocked down more than 60% upon induction of the expression of H1.3 shRNA by doxycycline (Fig. 3B ). This knockdown led to a 50% elevation in H19 mRNA transcripts (Fig. 3B) . To investigate whether H19 expression is affected specifically by H1.3 or by all H1 variants, we analyzed H19 expression in all six OV-3/H1 cell lines, which exhibited comparable levels of exogenous FLAG-H1s for each respective H1 variant (Fig. 3C) . H19 transcript level was dramatically suppressed in OV-3/H1.3 line as measured by RT-PCR but remained unchanged in cell lines overexpressing other FLAG-H1 variants in OVCAR-3 cells (Fig. 3C) . These results indicate that H19 is strongly and specifically repressed by H1.3 variant in OVCAR-3 cells.
Overexpression of H1.3 in OV-90, another ovarian epithelial cancer cell line with low expression of H1.3, also dramatically inhibited H19 expression and cell growth, whereas such effects were not observed when H1.1 was overexpressed in OV-90/ H1.1 cells (Supplementary Fig. S3A ). In contrast, knockdown of H1.3 by shRNA in SK-OV-3, an ovarian epithelial cell line with higher H1.3 protein levels, resulted in a 2-fold increase of H19 expression as well as a modest increase in cell growth rate (Supplementary Fig S3B) . Collectively, these results further support a specific inhibitory role of H1.3 on H19 expression and cell growth in ovarian epithelial cancer cells.
Epigenetic mechanisms of H19 repression mediated by H1. 3 Chromatin structure and epigenetic mechanisms play a key role in H19 expression regulation (32) . To investigate the potential mechanisms by which H1.3 regulates H19 expression in OVCAR-3 cells, we first analyzed the binding profiles of H1.3 across the entire H19 gene locus, including a 5.2-kb upstream regulatory region, by ChIP. H1.3 overexpression resulted in preferential accumulation of H1.3 at the entire H19 regulatory region, but H1.3 remained absent at the housekeeping gene GAPDH (Fig. 4) . While H1.1 exhibited similarly low endogenous expression as H1.3 in OVCAR-3 cells (Fig. 1E) , overexpression of FLAG-H1.1 in OVCAR-3 cells to comparable levels of FLAG-H1.3 in OV-3/H1.3(H) cells did not lead to such enriched occupancy at H19 locus ( Supplementary Fig. S4A ). Genome- Fig. S5 ).
H19 expression is controlled by the ICR located within the H19 upstream regulatory region. In humans, this region contains seven CTCF-binding sites, of which methylation status regulates binding of the insulator-binding protein CTCF (33, 34) and H19 expression. To determine whether increased H1.3 binding at H19 ICR leads to changes in DNA methylation at H19 ICR and CTCF-binding status, we analyzed the levels of DNA methylation and CTCF occupancy at this region by bisulfite sequencing and ChIP, respectively. Such analysis indicated that H19-ICR region is hypomethylated in OVCAR-3 (Fig. 5A) . While the global DNA methylation levels were not changed by H1.3 overexpression, as indicated by unchanged sensitivity to methylation-sensitive enzymes (Fig. 5B) , DNA methylation levels of CpG sites surrounding CTCF-binding sites were significantly increased in OV-3/H1.3(H) cells by 2.3-and 5.8-fold for region 1 and region 2, respectively (Fig. 5) . This level of increase in DNA methylation in OV-3/H1.3(H) cells was diminished by knockdown of H1.3 by shRNA (Fig. 5) , indicating that the increased occupancy of H1.3 at H19 distal promoter region leads to hypermethylation of the H19-ICR. In addition, compared with OVCAR-3 cells, CTCF occupancy at H19-ICR was reduced at region 1 and region 2 in OV-3/H1.3(H) cells, but not in OV-3/H1.1(H) cells (Fig. 6 and Supplementary Fig.  S4B ). The reduced occupancy of CTCF protein on H19-ICR in OV-3/H1.3(H) cells suggests that overexpression of histone H1.3 may prevent CTCF from binding to the H19 ICR region and regulating H19 expression in OVCAR-3 cells.
Taken together, these findings suggest that linker histone H1.3 directly regulates H19 expression in ovarian cancer cells by binding to H19-ICR, increasing DNA methylation and preventing CTCF from binding to CTCF sites in H19 ICR.
Overexpression of histone H1.3 and reduction of H19 synergistically suppress ovarian cancer cell growth Expression of H19 mRNA promotes proliferation and enhances tumorigenesis in several types of cancer cells (35) (36) (37) (38) . To determine whether the inhibitory effect of H1.3 on OVCAR-3 growth rate is mediated through its repression on H19 expression, we first investigated the effects of modulation of H19 expression on OVCAR-3 growth. Overexpressing H19 in OVCAR-3 by transfecting the cells with a pcDNA-H19 vector dramatically increased H19 transcripts (Fig. 7A) . This upregulation resulted in significant increase in cell growth rate in OVCAR-3 (Fig. 7B) . We were only able to moderately overexpress H19 in OVCAR-3/ H1.3(H) cells, which led to a moderate increase in growth rate of OVCAR-3/H1.3(H) cells, indicating that the growth inhibition in OVCAR-3 by H1.3 overexpression can be partially rescued by H19 upregulation.
We next determined whether overexpression of H1.3 and depletion of H19 transcript would synergistically impair the growth of ovarian cancer cells by further knocking down H19 transcript in OV-3/H1.3(H) cells using H19 shRNA. Induction of H19 shRNA led to a 75% and a 92% reduction of H19 expression in OVCAR-3 and OV3/H1.3(H) cells, respectively (Fig. 7C) . Depletion of H19 significantly reduced growth rate (Fig. 7D) , suggesting that overexpression of linker histone H1.3 and depletion of H19 transcript synergistically suppress the growth of OVCAR-3 cells.
Discussion
H19 is an oncofetal gene whose expression is frequently elevated in many solid tumors (10, 11, 13, 39) . Its upregulation has been associated with increased proliferation, tumorigenesis, cell-cycle progression, and cell migration (35, 36, 40, 41) . In this study, we uncovered a novel function of H1.3 in inhibiting ovarian cancer cell growth, likely mediated through repression of H19 gene (Supplementary Fig. S6 ). By using overexpression and knockdown approaches, we generated cell lines with modulated expression of histone H1 variants and H19 transcript. Systematic analysis of generated clones demonstrates that linker histone H1.3 is the specific somatic H1 variant capable of effective suppression of H19 in ovarian epithelial cancer cells. Our results also suggest that this regulation is likely to be a direct effect. In addition, overexpression of histone H1.3 represses the growth rate and colony formation ability in OVCAR-3 cells, suggesting its tumor suppressor properties. In contrast, similarly overexpressing H1.1 cells did not change the growth rate and clonogenicity of OVCAR-3 ( Supplementary Fig. S4 ). The synergistic effect of H1.3 overexpression and H19 depletion in ovarian cancer cells suggests a potential strategy of combining H1.3 modulation with H19 for therapeutic intervention.
We have investigated the mechanism by which H19 is suppressed by H1.3 and found that H1.3 preferentially accumulates at H19 ICR, leading to increased DNA methylation and reduced binding of CTCF insulator-binding protein at H19-ICR. These results suggest that H1.3 epigenetically represses H19 expression through DNA methylation as well as an antagonism between H1 and CTCF. Although a link between H1 and DNA methylation in regulating specific genes has been revealed in several previous studies (9, 42, 43) , our study is the first one demonstrating a highly specific regulation of H19 expression by a single H1 variant, H1.3, in vivo in ovarian cancer cells. Other H1 variants, when expressed to similar levels, do not repress the expression of H19 in OVCAR-3 cells (Fig. 3C) . Likewise, stably overexpressing H1.3, but not H1.1, leads to dramatic reduction in H19 expression and cell growth in OV-90 ovarian epithelial cancer cell line, and expressing H1.3 shRNA, but not scrambled shRNA, in SK-OV-3 ovarian epithelial cancer cells increases H19 expression and cell growth ( Supplementary  Fig. S3 ). The mechanism by which H19 is specifically repressed by H1. (Fig. 4 and Fig. 6 ). These binding patterns appear to be elicited specifically by overexpression of H1.3, as overexpression of H1.1 to similar levels does not lead to marked changes at this locus in OV-3/ H1.1(H) cells (Supplementary Fig. S4A and S4B) , suggesting a critical role of preferential binding of H1.3 at this locus in the H19 inhibition. H1 variants have distinct biochemical properties and differ significantly in their residence time on chromatin and ability to promote chromatin condensation in vitro, which is likely to contribute to their specificity in vivo (45, 46) . Other mechanisms may also contribute to the regulation of H19 by H1.3. For example, linker histone H1 has been shown to interact with SirT1, promoting gene silencing (47) . In vitro studies have shown that H1 interacts with heterochromatin protein HP1a (48) and stimulates polycomb-repressive complex 2 (PRC2) activity (49) . Therefore, the direct effect of H1.3 on H19 gene silencing may be due to interactions between linker histone H1 and other chromatin proteins or factors. In addition, histone H1 was found to inhibit human SWI/SNF nucleosome remodeling activity (50), thus it is also conceivable that histone H1.3 acts as a specific repressor of the H19 gene by blocking the chromatin-remodeling complex to access the H19 regulatory region. Histone H1 is increasingly being suggested to contribute to epigenetic regulation in cancer cells. Understanding the underlying molecular mechanisms may lead to new approaches to manipulate gene expression. In this study, we generated stable cell lines with tagged H1 variants, and we established inducible system in which protein levels of histone H1 variants can be readily modulated. Those cell lines will serve as valuable tools to study the role of H1 in epigenetic regulation in cancer cells. The identification of H1.3 being a potent repressor for H19 also suggests a novel function of H1.3 as a tumor suppressor in ovarian epithelial cancer cells.
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